FeesSafety
Pluang+

Bifrost (BFC) price drops 10.48% in an hour but gains 26.08% over 24 hours on Oct 23

Market News
23 Oct 2026
Tokenpost
View Source
Neutral
Bifrost (BFC) price drops 10.48% in an hour but gains 26.08% over 24 hours on Oct 23

On October 23, Bifrost (BFC) experienced a sharp price drop of 10.48% within one hour, falling to $0.025973. Despite this short-term decline, BFC's price rose 26.08% over the full 24-hour period, reaching a high of $0.029133. The token's market capitalization stood at approximately $36 million with a trading volume of over $27 million. Earlier, BFC had also gained 11.74% in a 30-minute span, nearing the $0.03 mark, indicating volatile but overall positive momentum for the day.

Bifrost (BFC) saw notable price swings on October 23, including a 10.48% drop within an hour and a 26.08% rise over 24 hours. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 23, 2026 20:03 WIB: Among 50 major cryptocurrencies priced on Pluang, 29 rose and 20 fell today. Key movers included EOS at Rp12.649 with an 8.13% increase, COTI at Rp211 with a 6.61% gain but a 62% sell order activity, and DOT at Rp21.473 with a 5.61% rise and 89% buy order activity.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
27 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App